# Vasa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vasa-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Encinitas, US
- Website: www.vasatherapeutics.com/
- Total disclosed funding: $3.3M
- Latest round: Seed (Dec 22, 2023)
- Investors on record: 3

## About

Based in California, US, and founded in 2019 by Chief Executive Officer Artur Plonowski, Vasa Therapeutics, Inc. operates as a healthcare-based company developing therapies that target the pathophysiology of cardiovascular aging. In January 2024, Vasa Therapeutics, Inc. raised USD 2.3 million in grant funding.

Vasa Therapeutics, Inc. has developed transformative therapies for diseases related to cardiovascular aging, heart failure, peripheral artery disease (PAD), and sarcopenia. The company offers VS-041, which is a medicine-based treatment for heart failure with preserved ejection fraction (HFpEF). In addition, the firm provides apelin peptide analogs, which are for obese patients at risk for skeletal muscle loss or cardiovascular disease. Vasa Therapeutics, Inc. offers an inhibitor of camKIId, a solution for heart failure and life-threatening arrhythmias.

The company plans to use the funding in January 2024 to expand its therapies for cardiovascular diseases.

## Funding rounds

- Seed, Dec 22, 2023, $3.3M — Orphinic Scientific, SeedFolio, NuFund Venture Group

## Investors

- Orphinic Scientific — Seed
- SeedFolio (https://capitalatlas.ai/funds/seedfolio) — Seed
- NuFund Venture Group (https://capitalatlas.ai/funds/nufund-venture-group) — Seed